A detailed history of Salem Investment Counselors Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Salem Investment Counselors Inc holds 167 shares of GALT stock, worth $207. This represents 0.0% of its overall portfolio holdings.

Number of Shares
167
Previous 167 -0.0%
Holding current value
$207
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

BUY
$3.61 - $5.0 $602 - $835
167 New
167 $1,000
Q3 2018

Nov 14, 2018

SELL
$3.68 - $6.93 $614 - $1,157
-167 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$3.16 - $9.16 $527 - $1,529
167 New
167 $1,000
Q1 2018

May 15, 2018

SELL
$3.78 - $5.97 $631 - $996
-167 Closed
0 $0
Q4 2017

Feb 16, 2018

BUY
$1.54 - $3.34 $257 - $557
167
167 $1,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $73.7M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Salem Investment Counselors Inc Portfolio

Follow Salem Investment Counselors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Salem Investment Counselors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Salem Investment Counselors Inc with notifications on news.